GlassScriptPhysician profile
Samih Hussein Raad
NPI 1497160600
$8,995.22
in general payments reported to CMS, 2019-2025
44 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $749 · 2021: $711 · 2022: $813 · 2023: $1,343 · 2024: $2,025 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,343 · Travel and Lodging: $886 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,343.08 |
| Travel and Lodging | $885.69 |
| Education | $255.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,469.32 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,270.78 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Intuitive Surgical, INC. | $896.44 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $894.09 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $364.88 | 2019-2025 | Winrevair |
| Mallinckrodt Hospital Products INC. | $341.20 | 2020-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $320.48 | 2019-2023 | Opsumit, Uptravi |
| Allergan, INC. | $276.35 | 2019-2020 | |
| United Therapeutics Corporation | $238.05 | 2019-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $222.05 | 2023-2024 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $201.45 | 2021-2025 | Glassia |
| Genzyme Corporation | $191.83 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $178.98 | 2024-2025 | |
| Insmed, INC. | $167.47 | 2024-2025 | Arikayce, Brinsupri |
| Lilly USA, LLC | $151.57 | 2025 | Zepbound |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samih Raad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.